DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 195 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $619 | -63.2% | 26,655 | -67.5% | 0.02% | -68.2% |
| Q1 2024 | $1,683 | +254.3% | 82,000 | +409.4% | 0.07% | +214.3% |
| Q2 2023 | $475 | +28.0% | 16,097 | 0.0% | 0.02% | +16.7% |
| Q1 2023 | $371 | -54.6% | 16,097 | -45.3% | 0.02% | -60.0% |
| Q4 2022 | $818 | -99.7% | 29,426 | +285.5% | 0.04% | +221.4% |
| Q3 2022 | $234,000 | -52.1% | 7,634 | -49.8% | 0.01% | -56.2% |
| Q1 2022 | $489,000 | +48.6% | 15,203 | +106.3% | 0.03% | -22.0% |
| Q4 2021 | $329,000 | -11.6% | 7,369 | 0.0% | 0.04% | -18.0% |
| Q3 2021 | $372,000 | -31.1% | 7,369 | -76.2% | 0.05% | -68.9% |
| Q4 2019 | $540,000 | – | 30,974 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |